pCR	pathological complete response
mPR	major pathologic response
AE	adverse event
OR	objective response
OS	overall survival
EFS	event-free survival
DFS	disease-free survival
PFS	progression-free survival
ORR	overall response rate
RFS	relapse-free survival
WT	wild type
HRQol	health-related quality of life
NSCLC	non-small cell lung cancer
SEER	Surveillance, Epidemiology, and End Results Program
PD-L1	Programmed Death Ligand 1
TPS	Tumor Proportion Score
HR	hazard ratio
CI	confidence interval
RR	relative risk
CT	chemotherapy
TIS	tislelizumab
BSC	best supportive care
PCSK9	proprotein convertase subtilisin/kexin type 9